Royalty Report: Drugs, Delivery, Pain – Collection: 368511


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Delivery
  • Pain
  • cardiac
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 368511

License Grant
Licensor grants an exclusive license throughout the Territory, with the right to grant sublicenses, under the Licensor Technology, to conduct the Development and Regulatory Program and the Commercialization Program, with respect to the Products including Licensor Technology which may result from the Development and Regulatory Program and to use, market, sell, have sold and distribute such Product in the Territory; provided, however, that nothing shall alter the rights of Licensor contained in this Agreement to manufacture the Product.
License Property
Initial Platform Technology, with respect to the Initial Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783, 181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvement thereto whether patentable or not.

Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.

Compound shall mean morphine sulfate and/or morphine polystyrene.

Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIAN® Referenced Product

KADIAN® NT shall mean the abuse deterrent form of the KADIAN® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.

Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIAN® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIAN® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.

Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.

Field of Use
The field of use for KADIAN is as an extended release morphine sulfate pain medication.

Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIAN® solid dose product line.

IPSCIO Record ID: 338651

License Grant
Licensor of Ireland grants the Licensee, also of Ireland, an exclusive, sublicensable license, solely in the field in the territory to use the Licensor technology, including intellectual property rights to sell and market and exploit the regulatory filings for the products in the field in the territory
License Property
LiquiTime® is a drug delivery platform for modified, extended and controlled release of liquid oral drugs.

Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.

The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).

Field of Use
Licensee has licensed rights to the LiquiTime® drug delivery platform for the U.S. Over-the-Counter (OTC) drug market.

The exclusive license includes Licensor’s LiquiTime® Ibuprofen and LiquiTime® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant.  These are the initial products.

IPSCIO Record ID: 203528

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts, an exclusive  license, without the right to grant any sublicense, under the Patent Rights and the Know-How to use and sell Product in the Territory. No license is granted for any other product than sustained release propranolol which is bio-equivalent to to lnderal LA.
License Property
Product shall mean any and all bulk or finished pharmaceutical products in solid oral dosage form which are  developed or manufactured using the Patent Rights or Know How that contain sustained-release propranolol as the active pharmaceutical ingredient and are intended to be bioequivalent to lnderal LA.

Patent Rights means
Application Serial No. 09/554,102   Filed May 4, 2000
Application Serial No. 09/555.095   Filed May 24, 2000

Field of Use
Inderal LA (Propranolol) is a beta-blocker used to treat high blood pressure, irregular heartbeats, shaking (tremors), and other conditions. It is used after a heart attack to improve the chance of survival. It is also used to prevent migraine headaches and chest pain (angina). Inderal LA is formulated to provide a sustained release of propranolol hydrochloride

IPSCIO Record ID: 2939

License Grant
An exclusive License Agreement that grants the Licensee an exclusive License to develop and commercialize Opana® and Opana® ER in Canada, Australia and New Zealand.  Regulatory approval must be received prior to any sale of the Licensed products.
License Property
Opana is in a group of drugs called narcotic pain relievers. It is similar to morphine.  Opana is used to treat moderate to severe pain.  Opana ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.
Field of Use
The rights granted apply to the healthcare industry relating to the drug market.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.